Representative staining of bone marrow aspirates collected from a patient at baseline and after 1 cycle of treatment with 45 mg/m2 selinexor + 20 mg dexamethasone,

Slides:

Advertisements

Similar presentations

Increased peripheral platelet destruction and caspase-3– independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients by.

Advertisements

Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,

The angiogenesis inhibitor vasostatin is regulated by neutrophil elastase–dependent cleavage of calreticulin in AML patients by Sarah Mans, Yara Banz,

How I treat HHV8/KSHV-related diseases in posttransplant patients by Giovanni Riva, Mario Luppi, Patrizia Barozzi, Fabio Forghieri, and Leonardo Potenza.

Platelet activation and inhibition in polycythemia vera and essential thrombocythemia by Carlo Patrono, Bianca Rocca, and Valerio De Stefano Blood Volume.

A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with.

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Phenotypic and Functional Changes Induced at the Clonal Level in Hematopoietic Stem Cells After 5-Fluorouracil Treatment by Troy D. Randall, and Irving.

Korde N et al. Proc ASH 2012;Abstract 732.

IDH1 mutant glioma cells are sensitive to TMZ

Immunologic effects of F16-IL2 therapy.

A Randomized Trial Of Daily Prednisone Versus Pulsed Dexamethasone In Treatment Naïve Patients With Idiopathic Thrombocytopenic Purpura by Johannes Matschke,

Multiple Myeloma: Interleukin-15 Antagonizes Bone Morphogenetic Protein-Induced Apoptosis and Growth Inhibition. by Magne Rekvig, Anne-Tove Brenne, Torstein.

Reduced tumor load in peripheral blood after treatment with G-CSF and chemotherapy in children with tumors of the Ewing sarcoma family but not neuroblastoma.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

BTK inhibition in myeloma: targeting the seed and the soil

Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets by Kartik Sehgal,

How I treat elderly patients with myeloma

A young patient with multiple myeloma

Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection by Koen Van Besien, Sonali Smith,

Relationship between urinary TNF-α and RANTES excretion

SOX11 holds mantle cell lymphoma’s key to home

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

by Alexander Röth, Andreas Hüttmann, Russell P

Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK–positive.

Detection of Trisomy 12 and Rb-Deletion in CD34+ Cells of Patients With B-Cell Chronic Lymphocytic Leukemia by B. Gahn, C. Schäfer, J. Neef, C. Troff,

TNT post hoc analysis: Improvement between baseline and final visit in estimated GFR by treatment group End point 10-mg atorvastatin 80-mg atorvastatin.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate by E.L.

ROCK and Rho(ll) in bone marrow

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma by Robert Marcus, Kevin Imrie, Andrew Belch,

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura? by Marc Michel, Nichola Cooper, Christelle Jean, Christine Frissora, and.

Yang et al. SALL4 is a key regulator of survival and apoptosis in human leukemic cells. Blood. 2008;112(3):805–813. Blood Volume 114(14): October.

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study by Daniel J. DeAngelo, Wendy.

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia by Parvathi Ranganathan, Xueyan Yu, Caroline Na, Ramasamy Santhanam, Sharon Shacham,

Chronic graft-versus-host disease

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.

by Geling Li, Emily Waite, and Julie Wolfson

by Kaiwen Chen, Matthew P. Cheng, Sarah P

BCR-ABL1 gene rearrangement as a subclonal change in ETV6-RUNX1–positive B-cell acute lymphoblastic leukemia by Karen A. Dun, Rob Vanhaeften, Tracey J.

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

(A through C) Mean eGFR during follow-up according to treatment assignment in patients with normoalbuminuria (A), microalbuminuria (B), and macroalbuminuria.

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

Hematopoietic potential of HEP from patient-specific iPSC may be reduced. Hematopoietic potential of HEP from patient-specific iPSC may be reduced. (A)

Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus.

Bridge to transplant following Bv+Bs regimen.

A case of lenalidomide-dependent myelodysplastic syndrome

by Wendy Lim, Sara K. Vesely, and James N. George

Bv+Bs regimen schedule.

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.

Overcoming “aspirin resistance” in MPN

Lifestyle intervention was associated with improved cardiorespiratory fitness. Lifestyle intervention was associated with improved cardiorespiratory fitness.

Treatment versus Transplant for Challenging Hematologic Disorders

Pain. Pain. (A) Skeletal pain experienced by bone marrow (BM) and peripheral blood stem cell (PBSC) donors at baseline, during the pericollection period,

Treatment algorithm for management of CRS based on the revised CRS grading system. Treatment algorithm for management of CRS based on the revised CRS grading.

Overview of the treatment protocol HLH-94

Resistance mechanism for ibrutinib in marginal zone lymphoma

How I treat hemophagocytic lymphohistiocytosis

Serum bicarbonate increased by ≥3, ≥4, and ≥5 mEq/L in 52%, 39%, and 22% of patients, respectively, in the combined TRC101 dose group compared with 6%,

Distribution of percent consistent facility aspirin use.

Pure red cell aplasia by Robert T. Means Blood

Suggested algorithm for bone marrow biopsy and skeletal imaging in patients with monoclonal gammopathy of undetermined significance. #Mayo Clinic Risk.

Patient Tregs express normal levels of suppression.

Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI by Naranie Shanmuganathan, Susan.

by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal

Cold agglutinin disease

Study design. aPatients initially receiving tenapanor 30 mg twice a day were allowed to down-titrate weekly (stepwise 30 → 20 → 15 → 10 → 3 mg twice a.

Distribution of facility mean treatment time, by DOPPS region and phase. Distribution of facility mean treatment time, by DOPPS region and phase. Restricted.

Presentation transcript:

Representative staining of bone marrow aspirates collected from a patient at baseline and after 1 cycle of treatment with 45 mg/m2 selinexor + 20 mg dexamethasone, twice weekly. Representative staining of bone marrow aspirates collected from a patient at baseline and after 1 cycle of treatment with 45 mg/m2selinexor + 20 mg dexamethasone, twice weekly. The patient achieved a best response of PR while on study. Staining shows increased apoptosis (Apoptag) and nuclear accumulation of known TSP cargoes of XPO1 (p53, survivin, Rb, and Smad4). Christine Chen et al. Blood 2018;131:855-863 ©2018 by American Society of Hematology